Effect of oxiracetam combined with edaravone on clinical efficacy and serum inflammatory factors in patients with acute cerebral infarction
10.7619/jcmp.201719009
- VernacularTitle:奥拉西坦联合依达拉奉治疗急性脑梗死的临床疗效及对血清炎症因子的影响
- Author:
Hong XU
1
;
Ye HUA
;
Zhigang FENG
;
Shuangshuang WU
;
Tao MA
;
Yumin LIU
;
Yunnan LU
Author Information
1. 江苏省无锡市第二人民医院神经内科
- Keywords:
oxiracetam;
edaravone;
acute cerebral infarction;
serum inflammatory factors
- From:
Journal of Clinical Medicine in Practice
2017;21(19):31-33
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the effect of oxiracetam combined with edaravone on clinical efficacy and serum inflammatory factors in patients with acute cerebral infarction and their influence on serum inflammatory factors.Methods A total of 68 patients with acute cerebral infarction were equally divided into observation group and control group by random number table method.All patients were given anti-stroke therapy.Patents in control group were given edaravone,while,patients in observation group were given oxiracetam on the base of control group.Then the clinical efficacy and adverse reactions of two groups were observed.The changes of NIHSS,C-reactive protein (hs-CRP),interleukin-6 (IL-6),tumor necrosis factor (TNF-α) levels were also measured.Results The total effective rate of observation group was 94.12％ and 76.47％ in the control group.The total effective rate of observation group was higher than control group (P ＜ 0.05).Both the basic cure rate and significant progress rate of observation group were also less than control group (P ＜0.05).The NIHSS,CRP,IL-6 and TNF-α levels of patients in two group decreased after treatment (P ＜ 0.05),and those indexes of observation group were much lower than that in the control group after treatment (P ＜ 0.05).Conclusion Treatment of oxiracetam combined with edaravone in patients with acute cerebral infarction can reduce the NIHSS and serum CRP,IL-6,TNF-α levels,and improve neurologic impairment.
